BMS's Dr Nathan Pennell outlines how biomarker testing barriers and trial diversity affect patient access to targeted oncology drugs.
Nathan Pennell
Advertisement
Nathan Pennell, MD, PhD, FASCO, is senior vice president, head of Hematology and Oncology Medical Affairs at Bristol Myers Squibb.
Articles by Nathan Pennell
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Iovance’s Lifileucel Reaches 52% Response Rate in Biomarker-Selected Lung Cancer Subgroup
2
Lilly’s Retatrutide Doubles Ozempic’s Weight Loss in First Phase 3 Head-to-Head Trial
3
3SBio and Pfizer’s PD-1×VEGF Bispecific Shows Durable PFS Gains in First-Line NSCLC
4
AbbVie Files BLA With FDA for Etentamig in Relapsed/Refractory Myeloma
5